Abstract

Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.
Original languageEnglish
JournalEndocrinology and Metabolism Clinics of North America
DOIs
Publication statusPublished - 2019

Cite this

@article{d76987a4462443eb92cafd43abf2f0a7,
title = "Cancer Risk in Transgender People",
abstract = "Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.",
author = "{de Blok}, {Christel J. M.} and Dreijerink, {Koen M. A.} and {den Heijer}, Martin",
year = "2019",
doi = "10.1016/j.ecl.2019.02.005",
language = "English",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",

}

Cancer Risk in Transgender People. / de Blok, Christel J. M.; Dreijerink, Koen M. A.; den Heijer, Martin.

In: Endocrinology and Metabolism Clinics of North America, 2019.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Cancer Risk in Transgender People

AU - de Blok, Christel J. M.

AU - Dreijerink, Koen M. A.

AU - den Heijer, Martin

PY - 2019

Y1 - 2019

N2 - Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.

AB - Gender-affirming hormonal treatment (HT) in transgender people is considered safe in general, but the question regarding (long-term) risk on sex hormone-related cancer remains. Because the risk on certain types of cancer differs between men and women, and some of these differences are attributed to exposure to sex hormones, the cancer risk may be altered in transgender people receiving HT. Although reliable epidemiologic data are sparse, the available data will be discussed in this article. Furthermore, recommendations for cancer screening and prevention will be discussed as well as whether to withdraw HT at time of a cancer diagnosis.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85063279421&origin=inward

U2 - 10.1016/j.ecl.2019.02.005

DO - 10.1016/j.ecl.2019.02.005

M3 - Review article

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

ER -